Immunotherapy in inoperable stage III non-small cell lung cancer: a review
This article summarizes the current status and ongoing clinical trials incorporating immunotherapy into the management of inoperable stage III nonsmall cell lung cancer.
Back to homepage
Respiratory
Easyhaler®: an overview of an inhaler device for day-to-day use in patients with asthma and chronic obstructive pulmonary disease
The aim of this article is to provide an overview of the scientific literature on Easyhaler, with the purpose of emphasising features that make it close to the concept of an ‘ideal’ inhaler for daily use in patients with asthma or chronic obstructive pulmonary disease.
Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice
This article analyses the effectiveness, clinical outcomes, and safety of mepolizumab in clinical practice.
Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?
This article is an indirect comparison among literature data, especially between OCS reduction studies (ZONDA-SIRIUS) and pivotal studies (SIROCCO-MENSA), evaluating whether the clinical efficacy and the steroid-sparing effect of benralizumab may represent an advantage over other compounds. This data could help the clinician in the decision process of treatment choice, within the different available therapeutic options for eosinophilic refractory severe asthma.
Agents to treat BRAF-mutant lung cancer
Keywords: dabrafenib, immunotherapy, lung neoplasm, protooncogene protein B-raf, trametinib. Citation: Bustamante Alvarez JG, Otterson GA. Agents to treat BRAF-mutant lung cancer. Drugs in Context 2019; 8: 212566. DOI: 10.7573/dic.212566 Contributions: Both authors contributed equally to the preparation of this review.
